Phaco-trabeculotomy + deep sclerectomy a success

Article

Phaco-trabeculotomy in addition to deep sclerectomy can offer significant reductions in intraocular pressure (IOP).

Phaco-trabeculotomy in addition to deep sclerectomy can offer significant reductions in intraocular pressure (IOP), according to a study published in the March issue of Acta Ophthalmologica Scandinavica.

Christoph Lüke and colleagues from the University of Cologne and the University of Tübingen, Germany examined a consecutive series of 15 patients with uncontrolled open-angle glaucoma and cataract undergoing combined glaucoma and cataract surgery. Phacoemulsifiaction and IOL implantation were conducted through a temporal incision in clear cornea. Trabeculotomy and deep sclerectomy were performed in the superior quadrant. Postoperative examinations were performed daily for one week and then one, three, six and 12 months after surgery.

Postoperative mean IOP at one day was significantly reduced to 14.2 mmHg whilst, at 12 months, the complete success rate, defined as <22 mmHg without medication, was 60%. Qualified success was achieved in 93.3% of subjects.

The mean number of anti-glaucoma medications fell to 0.4 (p<0.001) and visual acuity (VA) improved by a mean of 1.6 lines over baseline (p=0.021). Complications noted included choroidal de-roofing, inadvertent perforation of the trabeculo-descemetic membrane and non-identification of Schlemm's canal. The incidence of complications resulting from over-filtration was low but there was a relatively high incidence of hyphaemas (53%). All were trivial and quickly resolved and no severe complications were observed.

The authors believe that phaco-trabeculotomy and deep sclerectomy is able to provide significant IOP reductions whilst remaining a relatively safe procedure.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
© 2025 MJH Life Sciences

All rights reserved.